Get the Stockscreener App
0.337
1.75%
-0.006
After Hours:
.34
0.003
+0.89%
Scienture Holdings Inc stock is traded at $0.337, with a volume of 256.77K.
It is down -1.75% in the last 24 hours and down -27.90% over the past month.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
See More
Previous Close:
$0.343
Open:
$0.35
24h Volume:
256.77K
Relative Volume:
0.08
Market Cap:
$13.69M
Revenue:
$653.40K
Net Income/Loss:
$-20.19M
P/E Ratio:
-0.1863
EPS:
-1.8091
Net Cash Flow:
$-11.11M
1W Performance:
+4.33%
1M Performance:
-27.90%
6M Performance:
-53.77%
1Y Performance:
-61.70%
1-Day Range:
$0.3357
$0.37
1-Week Range:
$0.305
$0.37
52-Week Range:
$0.2382
$2.60
Scienture Holdings Inc Stock (SCNX) Company Profile
Name
Scienture Holdings Inc
Sector
Industry
Phone
(800) 261 0281
Address
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, POM, WGRX, HKPD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.337 | 13.53M | 653.40K | -20.19M | -11.11M | -1.8091 |
HITI
High Tide Inc
|
2.34 | 204.80M | 452.61M | -35.30M | 13.25M | -0.3863 |
PETS
Petmed Express Inc
|
2.35 | 49.22M | 182.67M | -64.87M | -22.92M | -3.1193 |
POM
Pomdoctor Ltd Adr
|
0.3429 | 36.38M | 0 | 0 | 0 | 0.00 |
WGRX
Wellgistics Health Inc
|
0.1441 | 14.45M | 23.34M | -101.27M | -11.74M | -1.2919 |
HKPD
Cellyan Biotechnology Co Ltd
|
0.6351 | 14.62M | 0 | 0 | 0 | 0.00 |
Scienture Holdings Inc Stock (SCNX) Latest News
Aug Decliners: Is Scienture Holdings Inc gaining market share2026 Macro Impact & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Dividend Watch: Is Scienture Holdings Inc stock a good pick for beginners2026 Top Gainers & Safe Swing Trade Setups - baoquankhu1.vn
Market Pulse: Is LEXXW forming bullish engulfing patternsTake Profit & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Market Recap: What is Scienture Holdings Incs debt to equity ratioRate Cut & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Scienture posts 216% revenue growth, plans second product launch By Investing.com - Investing.com Australia
Scienture posts 216% revenue growth, plans second product launch - Investing.com
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead - The Globe and Mail
Exclusive: Penny stock Scienture reports revenue surge, expanding market access in 2025 - MSN
SCNX PE Ratio & Valuation, Is SCNX Overvalued - Intellectia AI
Scienture reports 216% revenue growth, gross margin expansion By Investing.com - Investing.com Australia
Scienture Holdings Inc (MEDS) Reports FY2025 Earnings - AlphaStreet
Tempest Therapeutics, Inc. (TPST) Reports FY2025 Earnings - AlphaStreet
Scienture Holdings, Inc. 2025 Annual Report: Key Risks, Forward-Looking Statements, and Business Overview - Minichart
Scienture Holdings: Q4 Earnings Snapshot - marketscreener.com
Scienture reports 216% revenue growth, gross margin expansion - Investing.com
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update - The Globe and Mail
Scienture Holdings 10-K: $0.43M Revenue, $(2.70) EPS — ARBLI™ Launch Drives Growth - TradingView — Track All Markets
Scienture’s blood pressure drug drove 216% growth; overdose spray up next - Stock Titan
Scienture Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Scienture Holdings (NASDAQ: SCNX) outlines CNS, CVS drug launches and pipeline - Stock Titan
EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025 - Benzinga
Scienture Holdings Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Aug Decliners: Will Scienture Holdings Inc be affected by tariffsAnalyst Downgrade & Verified Entry Point Signals - baoquankhu1.vn
If You Invested $1,000 in Scienture Holdings, Inc (SCNX) - Stock Titan
Gap Down: What are analysts price targets for Scienture Holdings Inc2026 Technical Overview & Expert Approved Trade Ideas - baoquankhu1.vn
Exclusive: Scienture expands reach for opioid overdose treatment, with deals covering 60% of US institutional market - MSN
Scienture secures GPO deals for naloxone nasal spray By Investing.com - Investing.com Nigeria
Scienture Holdings regains compliance with Nasdaq listing requirements - MSN
Scienture Holdings files to sell 2.1M shares for holders - MSN
Scienture (SCNX) Co-CEO adds stock grants and converts preferred into common - Stock Titan
Scienture files $200M mixed securities shelf - MSN
Scienture secures GPO deals for naloxone nasal spray - Investing.com India
Scienture Holdings (SCNX) Co-CEO granted 500,000 restricted shares - Stock Titan
SCNX Expands Market Reach with New GPO Agreements - GuruFocus
SCIENTURE Broadens Commercial Access for REZENOPY, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - Bitget
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - The Manila Times
High-dose overdose spray REZENOPY set to reach 5,000 US care sites - Stock Titan
EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market SessionAcurx Pharmaceuticals (NASDAQ:ACXP), A - Benzinga
Total current assets of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
What makes Scienture Holdings Inc. stock attractive to growth funds2025 AllTime Highs & High Conviction Buy Zone Alerts - Naître et grandir
Why Scienture Holdings Inc. stock remains a top recommendationMarket Activity Recap & Daily Profit Focused Stock Screening - Naître et grandir
Is Scienture Holdings Inc. stock a top pick in earnings seasonWeekly Trade Review & Proven Capital Preservation Tips - Naître et grandir
Why Is Scienture Stock Rising Today? - Stocktwits
SCNX SEC FilingsScienture Holdings, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SCNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SCNX Earnings History & Surprises | EPS & Revenue Results | SCIENTURE HOLDINGS INC (NASDAQ:SCNX) - ChartMill
Aug Spikes: What is Scienture Holdings Incs market position2025 Big Picture & Community Supported Trade Ideas - baoquankhu1.vn
SCNX Should I Buy - Intellectia AI
Scienture Holdings, Inc.: Target Price Consensus and Analysts Recommendations | | US80880X1046 - marketscreener.com
Scienture Holdings Inc Stock (SCNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
3.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):